In this context, many clinical trials have evaluated EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib) in recurrent or progressive glioblastomas, or in newly diagnosed gliomas as a monotherapy or in addition to chemotherapy and/or radiotherapy [18]–[24]. This evidence concerns the gene EGFR and central nervous system cancer.